Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
246.85
+3.35 (+1.38%)
Products

Lilly's Donanemab Receives U.S. FDA's Breakthrough Therapy Designation For Treatment Of Alzheimer's Disease

Published: 06/24/2021 11:03 GMT
Lilly(Eli) & Co (LLY) - Lilly's Donanemab Receives U.S. FDA's Breakthrough Therapy Designation for Treatment of Alzheimer's Disease.
Eli Lilly - Intends to Submit Biologics License Application for Donanemab Under Accelerated Approval Pathway Later This Year on Data From Trailblazer-alz.